AST1002
Astrocytes, Mature, CTRL Line
IPSC derived
biological source
human
growth mode
Adherent
karyotype
2n=46
morphology
elongated, flat, astrocytic
shipped in
dry ice
storage temp.
−196°C
Application
These products provide unique and versatile tools for the study of central nervous system (CNS) disorders, such as Alzheimer′s disease (AD), Parkinson′s disease (PD), autism, schizophrenia, and amyotrophic lateral sclerosis (ALS), as well as for drug screening and toxicology applications in the neural space.
Biochem/physiol Actions
Control line, derived from integration free made iPSC line, mature astrocytes
Features and Benefits
This product contains cryo-preserved, pre-differentiated astrocytes derived from a footprint-free, karyotype normal human iPSC line. It was designed for customers to generate mature astrocytes using the optimized maturation medium and supplements (AST1050, AST1051 sold separately). Mature astrocytes can be obtained within 17 days. Shortly after seeding and recovery, the cells proliferate and need to be passaged a minimum of two times. In general, at 17 days post-seeding, the cell population will contain ≥80% Glial Fibrillary Acidic Protein (GFAP) positive astrocytes and ≤15% Tuj-1 positive neurons (neuronal class III β-tubulin).
Preparation Note
The cells need to be passaged a minimum of two times. See technical bulletin for additional details.
User must also purchase Astrocyte Maturation Medium, AST1050 (50mL) or AST1051 (250mL). Sold separately.
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Efficient generation of astrocytes from human pluripotent stem cells in defined conditions.
Shaltouki A, Peng J, Liu Q, Rao MS, Zeng X.
Stem Cells, 31, 941-952 (2013)
Yiping Yan et al.
Stem cells translational medicine, 2(11), 862-870 (2013-10-12)
Human pluripotent stem cells (hPSCs), including human embryonic stem cells and human induced pluripotent stem cells, are unique cell sources for disease modeling, drug discovery screens, and cell therapy applications. The first step in producing neural lineages from hPSCs is
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service